Skip to main content



) --

BioMarin Pharmaceuticals



) hit a new 52-week high Tuesday as it is currently trading at $39.21, above its previous 52-week high of $39.20 with 149,677 shares traded as of 10:35 a.m. ET. Average volume has been one million shares over the past 30 days.

BioMarin has a market cap of $4.47 billion and is part of the

health care

sector and


industry. Shares are up 12.4% year to date as of the close of trading on Friday.

Scroll to Continue

TheStreet Recommends

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates BioMarin as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. You can view the full

BioMarin Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center